Open-label oral treprostinil for Raynaud's
Official title: An Open Label Study to Assess Efficacy of Oral Treprostinil Titrated to 3.0mg Three Times Daily or Highest Tolerable Dose in 30 Patients With Symptomatic Primary or Secondary Raynaud's Phenomenon Resistant to Standard Vasodilatory Therapy
Run by Brigham and Women's Hospital · NCT07112183 · Data updated 2026-11-12
This trial will test whether oral sustained-release treprostinil (UT-15C) can reduce the number and severity of Raynaud's attacks in adults with frequent primary or secondary Raynaud's.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Brigham and Women's Hospital Academic / other |
| Drugs / interventions | immunotherapy |
| Locations | 2 sites (Boston, Massachusetts and 1 other locations) |
| Status | Recruiting |
| Started | October 15, 2025 |
| Main results expected | September 30, 2028 |
| Study ends | March 1, 2029 |
| Registry record updated | March 24, 2026 |
| Trial ID | NCT07112183 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (≥18 years) with refractory Raynaud's experiencing four or more attacks per week, including primary Raynaud's or Raynaud's secondary to connective tissue diseases, and who are on stable background vasodilator therapy if applicable.
✕Probably not a fit
Patients with infrequent attacks (fewer than four per week), pregnant individuals, or those with contraindications to prostacyclin analogs are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This open-label Phase 4 trial gives adults with frequent Raynaud's oral sustained-release treprostinil (UT-15C) and monitors their symptoms and attack frequency. Eligible participants must have at least four Raynaud's attacks per week and may have primary Raynaud's or Raynaud's secondary to connective tissue disease; background vasodilator medications are allowed if doses have been stable for at least three months. All participants receive the active medication (no placebo control) and outcomes focus on changes in attack frequency, severity, and related complications. The study is conducted at Brigham and Women's Hospital in Boston, Massachusetts.
Why it matters
Potential benefit: If successful, the medication could reduce the frequency and severity of Raynaud's attacks and decrease the risk of painful digital complications.
How similar studies have gone: Prostacyclin analogs such as treprostinil have shown benefit for digital ischemia and pulmonary hypertension in prior studies, but oral treprostinil specifically for Raynaud's has limited published evidence.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged ≥ 18 years 2. Active Raynaud's Phenomenon defined as patients with refractory RP having four or more RP attacks per week in the 4 weeks before inclusion in the study. 3. Patients with either: 1. Primary Raynaud's Phenomenon 2. Patients with Raynaud's secondary to connective tissue diseases (including scleroderma (SSc), limited scleroderma (CREST), mixed connective tissue disease (MCTD), primary Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), with diagnosis of the underlying rheumatic disease based on standard criteria. 4. If patients are on phosphodiesterase inhibitors (sildenafil, tadalafil or vardenafil), endothelin antagonists, alpha adrenergic antagonists, or calcium channel blockers, their dose must be stable, defined as 3-months with no change in dose or frequency. 5. If female of childbearing potential (FOCP), has demonstrated a negative beta HCG (human chorionic gonadotropin) serum pregnancy test, and agrees to comply with any applicable contraceptive requirements of the protocol 6. If female of non-childbearing potential, meets either of the following criteria: 1. Is in a postmenopausal state defined as no menses for 12 months without an alternative medical cause and follicle-stimulating hormone (FSH) level consistent with postmenopause (\>25 mIU/mL). If a participant is \>60 years old and has been amenorrheic for \>5 years, the participant may be enrolled with an FSH \<25 mIU/mL after discussion with the PI. 2. Has a documented hysterectomy, bilaterial oophorectomy, or salpingectomy. Exclusion Criteria: 1. Uncontrolled hypertension, diabetes mellitus, acute coronary or cerebrovascular event within 3 months, history of sympathectomy 2. Smoking within 3 months or smoking cessation using nicotine products 3. History of alcohol or other substance abuse within the previous year 4. Subjects with diverticulosis confirmed via endoscopic evaluation of the sigmoid colon with at least three diverticula noted 5. Subjects with moderate to severe liver disease, Child Pugh Class B or C 6. Subjects currently taking any other prostacyclin. 7. Pregnant or breast feeding or considering pregnancy in next 4 months 8. Was dosed in any clinical research study evaluating another investigational drug (including biologics) or therapy (including specific immunotherapy) within 30 days or 5 half-lives (whichever is longer) of an investigational biologic drug before the start of the screening period. 9. Any serious chronic, and/or unstable pre-existing medical, surgical, psychiatric or other condition that could interfere with the participant's safety, obtaining informed consent, or compliance with study procedures per investigator's discretion. 10. Hospitalization for any indication within 7 days before the start of screening.
Where it's running
-
Brigham and Women's Hospital
Boston, Massachusetts, United States Recruiting -
Brigham and Women's Hospital
Boston, Massachusetts, United States Not yet recruiting
Study contacts
- Principal investigator: Aaron B Waxman, MD, PhD — Brigham and Women's Hospital, Pulmonary Vascular Disease Program
- Study coordinator: Olivia G Vayer
- Email: ovayer@bwh.harvard.edu
- Phone: 6175259733
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Polish registry of heart nerve–targeting treatments (cardioneuroablation and cardioneuromodulation)
This registry collects information to see how nerve-targeting heart procedures work for adults with fainting, abnormal heart rhythms, or orthostatic problems.
-
One-day exercise test to see how brain and body react in epilepsy, cognitive disorders, Parkinson's, dementia, and related conditions
A one-day study tests how an acute bout of exercise changes brain function and bodily signals in people with certain neurological conditions compared with healthy individuals.
-
Training Independent Muscle Activation From a Common Source
A new surgical approach plus home training tests whether people with recent amputations or revision surgeries can gain improved muscle control.
-
Activity after Spinal Surgery Engagement
This trial tests whether a behavioral program helps people recover by being more physically active after lumbar spine decompression surgery.
-
Reach and Engagement of Genetic Education, Risk Assessment, and Testing Feasibility (GENET) for PDAC risk
This study tests whether online education plus a phone call from PanCAN helps Black, Latino/a, and Medicaid-enrolled people in Massachusetts learn about genetic and multi-cancer early detection testing and decide about getting tested.
-
Burnout and Safety in Home Hospital vs Brick-and-Mortar Hospitals
This study tests whether frontline clinicians in home hospital programs experience different burnout levels and workplace violence than those in traditional inpatient hospitals.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.